Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency

Type III hyperlipoproteinemia associated with apolipoprotein E deficiency

Subjects with type III hyperlipoproteinemia develop premature atherosclerosis and have hyperlipidemia due to an increase in cholesterol-rich very low density lipoproteins (VLDL) of abnormal electrophoretic mobility. Apolipoprotein E is a major protein constituent of VLDL and appears to be important for the hepatic uptake of triglyceride-rich lipoproteins. A new kindred of patients with type III hyperlipoproteinemia is described in which no plasma apolipoprotein E could be detected, consistent with the concept that type III hyperlipoproteinemia may be due to an absence or striking deficiency of apolipoprotein E.

The effect of short-term feeding of a high carbohydrate diet on HLD subclasses in normal subjects

Plasma HDL concentrations are effected by several perturbations, including certain dietary manipulations. In this study we have examined the effects of a one week ingestion of an isocaloric, fat-free, high-carbohydrate diet (CHO greater than 80% of calories) and the concentrations and compositions of plasma HDL subclasses. Eleven healthy normolipidemic volunteers (6 females, 5 males) took part in this study. Blood samples for lipoprotein analysis were drawn before and at the end of the dietary period and analyzed for lipoprotein lipid and apoprotein concentrations. Lipoproteins also were characterized by zonal ultracentrifugation. Our results show the following significant changes at the end of the dietary period: plasma concentrations of VLDL-TG, VLDL-cholesterol and total VLDL mass increased, whereas plasma concentrations of LDL-cholesterol, LDL mass and HDL-cholesterol and HDL mass, decreased. Plasma concentrations of apoprotein A1 decreased (from 133.3 +/- 7.7 to 108.1 +/- 8.6; mean +/- S.E.M., p less than 0.0004), and apoprotein A2 concentrations remained unchanged. This resulted in a drop in plasma ratio of ApoA1/ApoA2 (p less than 0.03). Since it has been shown that ApoA1/ApoA2 ratio is higher in HDL2 than HDL3, we examined the concentrations of these two subfractions, employing rate-zonal ultracentrifugation for their isolation. One week of ingestion of the study diet was followed by consistent decreases in HDL2 mass (from 84 +/- 15 to 44 +/- 16 mg/dl, mean +/- S.E.M.), with inconsistent changes in HDL3 mass, (from 254 +/- 18 to 222 +/- 13 mg/dl) resulting in significant decreases in HDL2/HDL3 mass ratio. Lipid analyses of these subfractions did not demonstrate major compositional changes. The alterations noted could be due to decreased HDL production, at least in part, but alterations in the interconversions of lipoproteins also could have played a role. The falls in HDL2 on a diet which should be "antiatherogenic" illustrate the difficulty of assessing the atherogenicity of any given diet solely by the changes it produces in the levels of circulating lipoproteins.

Concentration and distribution of human plasma apolipoprotein E

(1) A sensitive, specific radioimmunoassay for human apolipoprotein E is described. (2) The method gave a plasma apolipoprotein E concentration of 0.107 +/- 0.051 g/l n = 55) in normal subjects. This value increased significantly (to 0.179 +/- 0.088 g/l) in type II hyperlipoproteinaemia (n = 31, p less than 0.01). Type III subjects formed a distinct group whose mean plasma apolipoprotein E concentration was increased four fold over normal (p less than 0.001). The level in type IV subjects (0.136 +/- 0.056, n = 30) did not differ significantly from the normal value. (3) When plasma was subjected to gel filtration on columns of 6% agarose, apolipoprotein E was located in three regions. Peak I corresponded to very low density lipoproteins, Peak II to the area between very low density and low density lipoproteins and Peak III to the leading edge of the high density lipoprotein fraction. No E protein eluted from the column after high density lipoproteins. (4) In contrast, ultracentrifugation of plasma resulted in up to 40% of apolipoprotein E appearing in the lipoprotein-free (d greater than 1.21 kg/l) fraction. This protein appears to hae been stripped largely from high density lipoprotein during ultracentrifugation. (5) Compositional analysis of very low density, intermediate density and low density lipoproteins isolated by a cumulative flotation procedure showed that the apoE/apoB ratio was the same in the first two species but fell to a very low value in low density lipoproteins.

Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows

Patients with familial dysbetalipoproteinemia (F. Dys.), also called familial type 3 hyperlipoproteinemia, are homozygous for a mutant allele, Ed, that specifies an abnormal form of apoprotein (apo) E, a prominent constituent of remnant lipoproteins derived from very low density lipoproteins (VLDL) and chylomicrons. Apo E is thought to mediate the removal of remnant lipoproteins from the plasma by virtue of its ability to bind to hepatic lipoprotein receptors. In F. Dys. patients, remnant-like lipoproteins accumulate, apparently because of delayed clearance by the liver. In the current studies, we show that the abnormal protein specified by the Ed allele (apo E-D) from some, but not all, patients with F. Dys. has a markedly deficient ability to bind to low density lipoprotein (LDL) receptors. Apo E was isolated from eight control subjects and nine patients with F. Dys. and incorporated into phospholipid complexes. The complexes were tested for their ability to compete with human 125I-LDL or rabbit 125I-beta-VLDL fo binding to LDL receptors in four assay systems: cultured human fibroblasts, solubilized receptors from bovine adrenal cortex, liver membranes from rats treated with 17 alpha-ethinyl estradiol, and liver membranes from normal rabbits. The apo E-D from six of the nine patients with F. Dys. showed binding affinities for LDL receptors that were reduced by greater than 98% in all receptor assays (group 1 patients). All of these group 1 patients were unequivocally of phenotype apo E-D/D by the criterion of isoelectric focussing. The apo E from the three other F. Dys. patients showed a near normal binding ability in all four of the receptor assays (group 2 patients). One of these group 2 patients appeared to have the apo E-D/D phenotype by isoelectric focussing. In the other two patients in group 2, apo E-D was the predominant protein (phenotype, apo E-D/D), but traces of protein in the region corresponding to normal apo E (apo E-N) were also present. The difference between group 1 and group 2 patients was also apparent when the apo E was iodinated and tested directly for binding to liver membranes from rats treated with 17 alpha-ethinyl estradiol. The 125I-labeled apo E from a group 2 patient, but not a group 1 patient, showed enhanced uptake when perfused through the liver of an estradiol-treated rate, indicating that the receptor binding ability of apo E correlated with uptake in the intact liver. The current studies allow the subdivision of patients with F. Dys. into two groups. In group 1, the elevated plasma level of remnants appears to be due to a diminished receptor binding activity of the abnormal protein specified by the Ed allele; in group 2 patients, the cause of the elevated plasma level of remnants remains to be explained.

Characterization of monoclonal antibodies against human apolipoprotein E

From a single cell fusion, five stable hybridomas secreting antiapolipoprotein E (apo E) were obtained. The immunoglobulin (Ig)G subclasses containing the respective monoclonal antibodies were isolated and were used as the antibody component in a solid-phase radioimmunoassay. The binding of 125I-apo E to the insolubilized antibody was inhibited by unlabeled apo E but not by unlabeled apoproteins A-I, A-II, C-II, and C-III, or by low density lipoprotein immunodepleted of endogenous apo E. Competition curves were obtained with lipoprotein subfractions that had the same shape as those obtained with purified apo E. Apo E levels in normal and hyperlipidemic plasma were well correlated when measured by the five monoclonal antibodies and polyclonal anti-apo E, although differences in absolute values were observed. In normal subjects 34, 10, 20, and 36% of apo E was recovered in the very low density lipoprotein, low density lipoprotein, high density lipoprotein, and the d greater than 1.21-gl/ml fractions, respectively, whereas these values were 34, 7, 12, and 47%, respectively, in type III patients. All antibodies indicated the same subfraction distribution of apo E. The monoclonal antibodies reacted with all of the isomorphs of apo E. One of the antibodies could be clearly distinguished by its reactivity with chemically modified very low density lipoprotein.

Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase

Immunoaffinity chromatography has been used to study the determinants of sterol efflux and net transport from cultured fibroblasts to human plasma medium. Sterol efflux was highly (approximately 80%) dependent upon a minor lipoprotein fraction containing apolipoprotein A-I unassociated with other apolipoproteins. The remaining activity was associated with the lipoprotein-free fraction of plasma and could be replaced by apoprotein-free albumin. Efflux was independent of lecithin:cholesterol acyltransferase (EC 2.3.1.43) activity. Net transport (i.e., the excess of efflux over influx) was completely inhibited by inhibition of lecithin:cholesterol acyltransferase or its removal by affinity chromatography on immobilized antibodies to apolipoprotein A-I or D (components of the transfer complex in human plasma). In uninhibited plasma, efflux and net transport rates had similar kinetics, suggesting that these were linked functions and that net transport was initiated by a carrier-dependent efflux step that, in the absence of lecithin:cholesterol acyltransferase activity, was associated with an equivalent influx of free sterol to the cells and that, in the presence of lecithin:cholesterol acyltransferase, was associated with esterification and transfer protein activity. The cholesterol carrier lipoprotein function (approximately 5% of plasma apolipoprotein A-I) appears to be the first step of lecithin:cholesterol acyltransferase-linked sterol transport from cells.

Normotriglyceridemic abetalipoproteinemia. absence of the B-100 apolipoprotein

In the two genetic forms of abetalipoproteinemia described previously, recessive abetalipoproteinemia and homozygous hypobetalipoproteinemia, all lipoproteins that normally contain apolipoprotein B are absent from plasma. We describe here a new disorder in which normal low density and very low density lipoproteins are absent, but in which triglycerides are absorbed from the intestine and chylomicrons are present in plasma. The underlying molecular defect appears to be selective deletion of the hepatogenous B-100 apolipoprotein. The B-48 apolipoprotein found in chylomicrons is spared. These findings suggest that the two species of apolipoprotein B are under separate genetic control and that low density lipoproteins are not normally derived from chylomicrons.